Krakowska Akademia Neurologii Sp. z o.o.

Cracow 38 trials 16 recruiting

38 Registered trials

16 Currently recruiting

Organisation

Krakowska Akademia Neurologii Sp. z o.o.

Location

Cracow, Poland

Identifier

ORG-100046735

Address

Ul. Arianska 7/3, 31-505, Poland

Departments

-
616007: neurology
Centrum Neurologii Klinicznej
Krakowska Akademia Neurologii
N/A
N/D
NA
Neurology
Not applicable

Clinical trials at this site (38)

Search interface

A clinical trial to assess the safety of EXV-802 and EXV-801 and how well they work to reduce agitation symptoms in people with Alzheimer's … Pending

2024-517388-22-00 Agitation in Alzheimer's Disease Dementia 10
SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults with Focal Onset Seizures Pending

2025-520587-18-00 Focal Onset Seizures 4
MP: ADAPT Forward - Master protocol of a platform study to evaluate the safety and efficacy of multiple regimens in participants with Myasth… Recruiting

2025-522492-28-00 AChR-Ab Seropositive Generalized Myasthenia Gravis, Mya 4 2026-03-13
First-in-Human Study of RO7812653 Recruiting

2025-522101-37-00 Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cogn 1 2026-02-17
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting

2024-514499-42-00 Refractory Partial Onset Epilepsy 5 2025-03-12
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis Recruiting

2024-512126-29-00 Generalized Myasthenia Gravis 5 2025-02-25
Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla… Recruiting

2023-507746-83-00 Generalized Myasthenia Gravis 5 2024-11-27
Randomised, double-blind, placebo-controlled study to assess safety and efficacy of PRI-002 in patients with MCI or mild dementia due to Alz… Recruiting

2022-503148-41-00 Alzheimer's disease 4 2023-12-01
A Study to Compare the Efficacy and Safety of Prasinezumab with a placebo in Participants with Early-Stage Parkinson’s Disease Recruiting

2025-522683-32-00 Early-Stage Parkinson’s Disease (PD) 5 2026-01-15
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Recruiting

2024-515979-35-00 Generalized Myasthenia Gravis 5 2025-11-13
A Phase 3b open-label, randomised study of IPX203 in subjects with advanced Parkinson’s disease and motor fluctuations - ADIP study Recruiting

2025-521772-57-00 Motor fluctuations in advanced Parkinson’s disease 5 2025-11-06
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing chronic migraine Recruiting

2024-515682-34-00 Chronic migraine 5 2025-10-06
A clinical trial to evaluate efficacy and safety of Xeomin® injections for preventing episodic migraine Recruiting

2024-515715-22-00 Episodic migraine 5 2025-10-06
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of remibrutinib in patient… Recruiting

2023-510026-32-00 Generalized Myasthenia Gravis 5 2025-06-11
A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy, safety, and tolerability of iptacopan in patients w… Recruiting

2023-507064-39-00 generalized Myasthenia Gravis 5 2024-09-26
Efficacy and Safety Study of Nipocalimab IV Infusions for Adults With Generalized Myasthenia Gravis Recruiting

2023-504152-97-00 Generalized Myasthenia Gravis 5 2021-11-26
A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting

2023-507202-14-00 Upper limb spasticity after stroke or traumatic brain i 7 2021-04-29
A Randomized, Double-blind, Parallel-group Study to Compare Pharmacokinetics, Pharmacodynamics, Clinical Effects, and Safety between ABP 692… Ended

2024-512914-16-00 Relapsing-remitting Multiple Sclerosis 5 2025-09-12
A study to assess efficacy and safety of efgartigimod PH20 SC in adults with ocular myasthenia gravis Ended

2024-514133-38-00 Ocular Myasthenia Gravis 5 2025-03-19
A study of safety and tolerability (acceptability of potential side effects) of exidavnemab, at 2 different doses, in patients with Parkinso… Ended

2024-511222-30-00 Multiple System Atrophy 4 2024-10-22
A Phase 3 study to evaluate the Efficacy and Safety of Efgartigimod IV in Patients with Acetylcholine Receptor Binding Antibody Seronegative… Ended

2024-511796-15-00 Acetylcholine Receptor Binding Antibody Seronegative Ge 5 2024-10-16
A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended

2023-504827-17-00 Chronic migraine 5 2024-03-18
A study to evaluate the effectiveness and safety of Dysport® for the prevention of episodic migraine in adults Ended

2023-504839-40-00 Episodic Migraine 5 2024-03-18